NCT02684084View on ClinicalTrials.gov

Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema

PHASE4TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

December 31, 2016

Conditions
Diabetic Macular Edema
Interventions
DRUG

Ozurdex

OZURDEX® (DEX implant; Allergan Inc. Irvine, CA, USA) is a sustained-release biodegradable implant approved for treatment of Macular Edema secondary to central retinal vein occlusion as well as noninfectious uveitis affecting the posterior segment

DRUG

Lucentis

LUCENTIS® (0.5 mg ranibizumab or RBZ, an anti-neovascular VEGF-A inhibitor, Novartis Pharmaceuticals Canada Inc.) was the first approved medical treatment for DME

Trial Locations (2)

M3C 0G9

Toronto Retina Institue, Toronto

M3N 2V6

North Toronto Eye Care Laser and Eye Specialists, Toronto

Sponsors

Collaborators (1)

Allergan
All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

North Toronto Eye Care Laser and Eye Specialists

OTHER